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Abstract
Effective diagnosis and surveillance of complex multi-factorial disorders such as cancer can be improved by screening of
easily accessible biomarkers. Highly stable cell free Circulating Nucleic Acids (CNA) present as both RNA and DNA species
have been discovered in the blood and plasma of humans. Correlations between tumor-associated genomic/epigenetic/
transcriptional changes and alterations in CNA levels are strong predictors of the utility of this biomarker class as promising
clinical indicators. Towards this goal microRNAs (miRNAs) representing a class of naturally occurring small non-coding RNAs
of 19–25 nt in length have emerged as an important set of markers that can associate their specific expression profiles with
cancer development. In this study we investigate some of the pre-analytic considerations for isolating plasma fractions for
the study of miRNA biomarkers. We find that measurement of circulating miRNA levels are frequently confounded by
varying levels of cellular miRNAs of different hematopoietic origins. In order to assess the relative proportions of this cell-
derived class, we have fractionated whole blood into plasma and its ensuing sub-fractions. Cellular miRNA signatures in
cohorts of normal individuals are catalogued and the abundance and gender specific expression of bona fide circulating
markers explored after calibrating the signal for this interfering class. A map of differentially expressed profiles is presented
and the intrinsic variability of circulating miRNA species investigated in subsets of healthy males and females.
Citation: Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW (2011) Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures. PLoS ONE 6(6):
e20769. doi:10.1371/journal.pone.0020769
Editor: Andrew Francis Hill, University of Melbourne, Australia
Received February 10, 2011; Accepted May 8, 2011; Published June 17, 2011
Copyright:  2011 Duttagupta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support for this work was provided by Affymetrix Inc which employs all authors (with the exception of RCG who is an employee of Genisphere LLC).
Genisphere LLC contributed the resources for the generation of the Leukocytic dataset. Affymetrix contributed all other resources necessary for the development
of the presented methods and conclusions and played a role in study design, data collection, analysis and decision to publish.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: the authors RD, RJ, JG and KWJ are employees of Affymetrix.
Inc. RCG is an employee of Genisphere, LLC. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: Keith_Jones@affymetrix.com
Introduction
A considerable proportion of the animal genome representing
both DNA and coding/non-coding RNAs can be detected in
circulation. Identified first in 1948 and thought to originate as
products of apoptosis or active release from cells, extracellular
circulating DNA fragments ranging in size between 500 bp to
greater than 30 Kb have been characterized both in normal and
diseased individuals [1,2]. Although the physiological functions of
these circulating species are unclear, the presence of tumor
associated genetic alterations in these molecules combined with
inherent molecular stability makes them attractive substrates for
disease detection, tracking and prediction. Of the various classes of
circulating nucleic acids – miRNAs, characterized by highly
conserved small non-coding RNAs of 19–25 nt in length and
representing approximately 1–2% of the known genes in
eukaryotes [3] are particularly attractive candidates. Approxi-
mately 940 mature miRNAs have been characterized to date in
humans [4,5,6] and it is believed that approximately 30% of all
annotated human genes may potentially be targeted by miRNAs
through post-transcriptional mechanisms [7]. The number of
targets is likely to increase when taking into account widespread
unannotated transcription [8] - thus making these molecules a
powerful regulatory class with the potential to intercept a wide
network of fundamental cellular processes. Over the past several
years an increasing number of miRNAs have been implicated in
cancer development with mechanisms ranging from copy number
alterations/mutations/epigenetic silencing or dysregulated tran-
scriptional control of miRNA loci [9,10]. These data reveal the
oncogenic and tumor suppressive nature of miRNAs and highlight
not only the correlation between various cancers and differential
miRNA signatures but also underscores the emergence of these
molecules as a critical class of diagnostic biomarkers. The ability to
profile miRNAs in circulation thus represents a non-invasive
opportunity to investigate disease-specific miRNAs and is a
promising alternative approach to current strategies for cancer
surveillance. Evidence for the involvement of secretory miRNAs in
pathogenic conditions are numerous [11,12], and range from
elevated levels of hsa-miR-155, hsa-miR-21 and hsa-miR-210 in
patients with diffuse large B cell lymphoma [13], over-expression
of hsa-miR-141 in individuals with prostate cancer [14] to up-
regulation of hsa-miR-24 and hsa-miR-31 in squamas cell
carcinoma of the oral cavity [15].
A critical prerequisite for developing circulating miRNA-based
diagnostics is the ability to accurately isolate and measure represen-
tative miRNA species in biofluids. In spite of high concentration of
RNAses in plasma and serum, circulating miRNAs are surprisingly
tractable. Some of the key molecular properties of these species include
(1) high stability in circulation and the ability to survive unfavorable
physiological conditions such as extreme variations in pH and multiple
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reflecting disease burden [11] and (3) protected from degradation
though inclusion in RNA binding proteins [18] or sub-cellular particles
such as exosomes or microvesicles [11,19] distinct from the
hematopoietic cellular population. All of these cellular attributes are
susceptible to a variety of pre-analytic factors involving sample
collection, processing, storage and extraction methods that can
determine both the quantitative and qualitative effectiveness of this
species for clinical use. In an effort to standardize results and bring
uniformity to data quality several studies over the past few years have
begun to explore and put forward recommendations for a subset of
these pre-analytical variables [14,16,17,20]. In this report we explore
the contribution of cellular miRNAs of hematopoietic origin in the
isolation and analysis of cell-free circulating miRNAs. We find
considerable proportions of miRNAs derived from Red and White
Blood Cells, present as contaminants in plasma preparations with the
potential to mask the intensities of truly circulating miRNA species. A
sample extraction pipeline is proposed that optimizes the integrity and
detection of cell-free RNA while minimizing the presence of interfering
cellular miRNAs. An application of th i sa p p r o a c hi sd e m o n s t r a t e di n
the analysis of inter-individual variability in normal cohorts of male and
female individuals. Maps of circulating miRNAs are presented after
extracting out interfering signals from miRNAs of cellular origin.
Furthermore gender specific signatures in the profiles of male and
female individuals are discussed. Taken together these data underscore
the importance of cellular miRNA signatures as yet another variable in
interpreting the complexity of circulating miRNA profiles.
Results
1. Fractionation of blood plasma and profiling of cellular
miRNAs
Conventional protocols for isolation of plasma (the non-cellular
component of blood that remains after removal of cells by
centrifugation) involves variable combinations of individual or
multiple low/high speed centrifugation steps. In order to assess
the contribution of these differential spin steps in the removal of
cellular material, we sought to fractionate whole blood from 17
healthy male Caucasian donors (Table S1) through successive
centrifugation rounds and investigate the proportion of cell free
and cellular miRNAs at each stage (Fig. 1). Samples were initially
segregated at a low speed spin to generate plasma (Cloudy
Supernatant) along with three cellular fractions: (1) Red Blood
Cells (RBCs), (2) the Buffy Coat consisting of platelets and White
Blood Cells (WBCs) and (3) pure populations of leukocytes
isolated by sub-fractionation of blood through Ficoll-Hypaque
gradients (Leukocytes). Since these populations represent the
major cellular constituents of blood, we hypothesize them to be
the primary contributor of cellular material through either cell
carryover or lysis during blood fractionation and collectively
define them as contaminant miRNAs. We further segregated the
plasma derived cloudy supernatant layer through increasing
centrifugal forces into supernatant (S1 and S2) and pellet (P1 and
P2) fractions. The supernatant fractions are representative of
primarily cell-free circulating RNAs with the pellet fractions
characterizing contaminating cellular particles. Amongst the
pellet class – the P1 and P2 fractions are distinct in both size
and granularity of the isolates. A prominent precipitate is
distinguished in the P1 fraction while the P2 fraction has
inconsequential cellular particles. All eight fractions (Fig. 1) were
extracted using Trizol-LS (Invitrogen) and the mirVANA filters
(Ambion) and subsequently hybridized to the Affymetrix miRNA
arrays. Integrity of extracted RNA was evaluated by Bioanalyzer
or Polyacrylamide Gel Electrophoresis and for all fractions
samples were found to be of robust quality (Fig. S1). On analysis
of the data, we observe distinct gradients in intensity distributions
in all of the 5 plasma derived classes compared to the
contaminant miRNAs (Fig. 2A). Fractions isolated with minimal
Figure 1. Fractionation Workflow. Separation of whole blood into distinct fractions: WBC, RBC, Leukocytes and CS, S1, S2, P1, P2 through
differential centrifugation. Total RNA was extracted from each fraction and hybridized to miRNA arrays.
doi:10.1371/journal.pone.0020769.g001
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contaminant rich (P1 and P2) display a greater magnitude of
signal intensity compared to supernatant fractions of S1 and S2.
Taken together these distributions indicate the presence of
miRNAs of distinct abundances in the cellular and circulating
class and highlights the prevalence of low-abundant species in
plasma fractions clarified through successive purification steps.
2. Correlation of miRNA intensities between individual
fractions and contaminant class
Since the process of sequential centrifugation is hypothesized to
result in the segregation of cellular material, we anticipate an
increased concentration of contaminant miRNAs in the pellet
fraction compared to the clarified supernatant derived from each
centrifugation step. Consequently we hypothesize a greater
Figure 2. Profiling of blood derived fractions and correlation of miRNA intensities between individual fractions and contaminant
class. (A) Box plots representing background subtracted non-normalized and summarized log2 intensities of human miRNAs (white) and background
probes (red) from each fraction. The black bar represents the median of each distribution. The open circles represent the outliers. (B) Counts of
detected features in Leukocytes (L), WBC (W) and RBC (R) constituting the contaminant profile. (C) Heat map of Spearman’s Rank Correlation
coefficients of the highest expressing 100 miRNAs across all 5 plasma fractions (CS, S1, S2, P1 and P2). The contaminant class is designated as LWR
and represents 313 miRNAs derived from the union of the Leukocytes, WBC and RBC fractions. Correlation values are shown in the bar scale.
doi:10.1371/journal.pone.0020769.g002
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cellular RNAs and the pellet fraction, compared to the supernatant
fractionsofS1and S2.Inorder to assessthe concordanceindetected
miRNAs between the cellular and each of the plasma derived
fractions we first computed the common set of all detected miRNAs
in the three contaminant classes. A total of 313 features (Table S2)
were identified through a union of WBC, RBC and Leukocytes
fractions based on the number of detected features in each fraction
assessed through the Wilcoxon - Rank Sum Test (Fig. 2B). These
features were then used to compute Spearman’s rank correlations
with the top 100 highest expressing miRNAs derived from the
centrifugation of whole blood into 5 plasma-derived fractions (CS,
S1, S2, P1 and P2) (Fig. 2C). We observe a stronger correlation
between the CS and P1 fraction with the contaminant list consistent
withthehypothesisthatthesefractionsareenrichedincell-associated
miRNAs. A reduced correlation is observed for fractions derived
from CS (S1, S2 and P2) indicating a progressive clarification of
contaminating miRNAs through removal of cellular particles with
subsequent centrifugation steps. Interestingly a strong agreement is
also observed between S1 and the S1 derived S2 and P2 fractions
suggesting that there is no additional advantage in sub-fractionating
the S1 sample. Taken together these results indicate that there is a
considerable proportion of cellular material that persist in the CS
fraction of plasma after the initial spin which can be sufficiently and
adequately removed by only one additional low speed centrifugation
step. The supernatant fraction (S1), derived after centrifugation
display low levels of contaminating miRNAs (Fig. 2C) consequently
leading to an enrichment of circulating miRNA species.
3. Concordance in expression levels of circulating miRNA
species between the plasma derived classes
In order to ensure that sub-fractionation of the CS into the S1
and P1 categories did not result in the loss of true circulating
miRNA species, we assessed the concordance in intensities
between the CS and ensuing S1 and P1 fractions to determine
their extent of similarity. Spearman’s Rank Correlation analysis
was performed on all detected miRNAs after removal of
contaminant features in the 3 samples (CS, S1 and P1). The
filtered miRNAs were first stratified into different intensity bins
consisting of highest expressing 20, 35, 50 and 100 miRNAs based
on average intensity levels across all fractions (Fig. 3A–D) and
correlation values calculated for each pair. We observe strong and
improved rank order correlations between the CS and S1 fractions
(rank correlations .0.6) compared to the CS, S1 and P1 fraction
pairs (rank correlations ,0.0). This implies that the composition of
the P1 fraction is distinct from the CS and S1 fractions and
consists of unique species of miRNAs. In contrast the strong rank-
order correlation between the CS and the S1 class demonstrates
the presence of homogenous populations of miRNAs, indicating a
preservation of miRNA species between the two plasma fractions
through the fractionation process.
4. Comparison of expression levels of circulating and
cellular miRNAs in the CS and S1 fractions
Since the process of sub-fractionation may impact both the
integrity and abundance of miRNAs, we wanted to ensure that
markers that were conserved between the CS and the S1 fractions
did not vary in their expression levels. In order to test this,
categories of miRNAs that are common to both these fractions
were selected after filtering for contaminants and stratified into
different intensity bins consisting of the top 20, 35, 50 or all of the
534 miRNAs (total number of features that remain after removal
of 313 contaminant miRNAs). We observe no significant
difference in the expression levels for any of these miRNA classes
in either of the supernatant fractions (two sided Student’s t–test,
with p-values ranging from 0.053 to 0.596) (Fig. 4A). This
indicates that most miRNA species remain intact through the
separation process from CS to S1. In addition, since the isolation
process is predicted to remove contaminant miRNAs we anticipate
higher proportions of cellular RNAs in the CS fraction compare to
the S1 class. To directly test this we similarly compared expression
levels of cellular RNAs stratified into different intensity tiers
between the two plasma derived fractions. For all miRNA strata
compared, we observe a statistically significant down regulation in
abundances for cellular miRNAs in the S1 class with a p-value of
,2.3e212 (Fig. 4B). This indicates a clarification of these RNAs
from the CS to the subsequently derived S1 class as a consequence
of the fractionation process. Taken together these result suggests
that isolation of the S1 class from the CS minimizes the levels of
contaminating cellular RNA, while preserving the expression of
circulating miRNA species.
5. Stability of expression of circulating miRNAs across
biological replicates
In principal the process of sub-fractionation, while removing
contaminants may potentially impact the stability of expression of
the truly circulating miRNA species. In order to assess if the
population of miRNAs detected in the CS and S1 fractions display
consistent patterns of expression, we analyzed both the rank order
concordance of miRNAs in the CS and S1 fractions across all
biological replicates and the distribution of the Coefficient of
Variance (CV) between these two fractions for all miRNAs within
the replicates studied. We hypothesized that conserved and stably
expressed miRNAs would have non-stochastic expression levels
and hence demonstrate not only high rank order correlations but
also low CV estimates. In order to test this, miRNAs were selected
after filtering out contaminant features and a common set of
targets isolated based on average intensities from the CS and S1
fractions across multiple biological replicates. Categories of
miRNAs were stratified into intensity bins containing the highest
expressing 20, 50, 200 or 534 miRNAs and Spearman’s Rank
Correlation values computed for each category per individual
fraction across all samples (Fig. 5A). Our results show modest
improvement in the mean correlation values for the CS fractions
across the different intensity strata (Fig. 5B). In contrast we observe
a statistically significant 2.5 fold increase in correlation in the S1
fraction as the analysis is restricted from the entire 534 features to
the highest expressing top 20 miRNA class (P-value of 9.624552e-
18 from two-sided Student’s t-test). Additionally the comparison of
variance between the different fractions across all replicates also
reveal a statistically significant higher variance for the CS fraction
compared to the S1 isolate for the entire spectrum of 534 miRNAs
(p-values of 6.138508e-13 from Student’s t-test) (Fig. 5C). Taken
together these results indicate that the population of miRNAs in
the S1 fraction is homogenously expressed across replicates with
significantly lower variability than species measured in the CS
fraction. Additionally the process of fractionation of CS into S1
tends to preserve the integrity of the higher expressed miRNAs
with no additional negative impact on the lower abundant species.
The S1 fraction hence represents a comprehensive plasma
category enriched in circulating markers that can be reproducibly
detected in replicate samples for biological analysis.
6. Variability in expression of circulating miRNA species in
cohorts of normal males and females
The intrinsic variability in expression of a biomarker is a critical
determinant for understanding both its normal behavior as well as
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characteristics of circulating miRNAs, we investigated both the
intensity and variability of expression of markers isolated from the
S1 fraction in cohorts of normal individuals. Samples extracted
from 8 male and 10 female Caucasian donors were background
adjusted, quantile normalized and the summarized intensities for
all microRNA and background probes analyzed (Table S1 and
Fig. S2). In order to ensure that markers displaying a wide range of
expression values were included in this analysis, individual
miRNAs were selected upon presence/absence calls and catego-
rized based on a 50% detection threshold amongst the 18
individuals. Two categories of miRNAs were defined in the S1
fraction: (1) 140 miRNAs present in both circulation (designated as
S) and those that map cumulatively to the contaminant profile
derived from WBC, RBC and Leukocytes (designated as L): (+S/
+L) and (2) 47 miRNAs present in circulation only: (+S/2L)
(Table S3, Fig. S3). The variability in each class was assessed
through Coefficient of Variance (CV) estimates. We observe a
statistically significant reduction in both intensities (p-value of 2.2e-
16 from two-sided Student’s t-test) (Fig. 6A) and CV measure-
ments (p-value of 0.023) (Fig. 6B) in the circulating class (+S/2L)
compared to miRNAs that are co-detected both in circulation and
contaminants (+S/+L). This result demonstrates that the variabil-
ity in expression of circulating miRNA species in a population is
reduced after removal of signatures originating from contaminat-
ing cellular miRNA profiles. Furthermore, examination of the 47
circulating miRNAs reveals greater than two-fold dynamic range
of intensity for this class (Fig. S3) and harbors candidates that bear
evidence of expression derived from tissues of non-hematopoietic
origin. Specifically we find hsa-miR-122 to be the highest
expressing circulating miRNA in our current dataset with tissue
specific expression derived from the liver (Fig. S3) [21,22]. Our
analysis therefore clearly distinguishes the effects on classification
and variability that arise due to varying levels of cell-derived
miRNAs in samples and underscores the importance of isolation
practices for the study of circulating species.
Figure 3. Concordance of expression levels of circulating miRNA species between the CS, S1 and P1 fractions. (A–D) Heat map of
Spearman’s Rank Correlation coefficients for the highest expressing 20, 35, 50 and 100 miRNAs present in CS, P1 and S1 fractions after removal of
contaminant features. The correlation values are shown in the bar scale.
doi:10.1371/journal.pone.0020769.g003
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20769Figure 4. Comparison of expression levels of circulating and cellular miRNAs in the CS and S1 fractions. (A) Intensity distributions from
the highest expressed 20, 35, 50 or all 534 human miRNAs in the CS and S1 fractions after removal of contaminant features. P-values from paired
Student’s t-tests, contrasting the intensities for each pair of conditions are reported. (B) Intensity distributions from the highest expressed 20, 35, 50
or all 313 contaminant miRNAs in the CS and S1 fractions with p-values from paired t-tests measuring significance.
doi:10.1371/journal.pone.0020769.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20769Figure 5. Correlation of expression levels of circulating miRNAs across different biological replicates in the CS and S1 fractions. (A)
Spearman’s Rank Correlation coefficients for CS and S1 fractions, across all replicates restricting to the highest expressing 20, 50, 200 or 534 (all)
human miRNAs that are common to the 2 fractions. Each point on the graph represents the rank correlation values across all pair-wise combination of
replicates for the category under study. (B) Mean correlation values for the CS and S1 fraction in each intensity strata. (C) Analysis of Coefficient of
Variance of the CS and S1 fractions for the 534 miRNAs under study.
doi:10.1371/journal.pone.0020769.g005
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circulating miRNAs
We next wanted to determine if there were subsets of miRNAs in
our dataset that demonstrated gender specific expression in
populations of normal male and female individuals. To distinguish
this we performed Significance Analysis of Microarrays (SAM) [23]
ontheentirecollectionof534miRNAsderivedfrom 8malesand10
female individuals after removal of contaminant features. We find a
total of 5 features to be significantly differentially expressed between
males and females at a False Discovery Rate of 5% (Fig. 7A).
Removal of one undetected feature based on Wilcoxon - Rank Sum
Test yield a subset of 4 differentially expressed circulating miRNAs
present as significant gender-specific discriminators in the individ-
uals studied (Fig. 7B and C and Fig. S4). Through an analysis of
intensity distributions and q-value estimates [24], we find all of the
4 miRNAs (hsa-miR-548-3p, hsa-miR-1323, hsa-miR-940 and
Figure 6. Variability of circulating miRNA expression levels in normal cohorts of male and female individuals. (A) Box plot of intensity
distributions of 140 features common to both circulation and in contaminants (+S/+L) or 47 features specific only to circulation (+S/2L). The black bar
represents the median of each distribution. The open circles represent the outliers. (B) Analysis of Coefficient of Variance of these two categories.
P-value from two-sided Student’s t-test measuring tests of significance is reported.
doi:10.1371/journal.pone.0020769.g006
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20769Figure 7. Analysis of differentially expressed miRNA species present in gender specific categories. (A) Comparison of observed versus
the expected scores obtained by SAM analysis of all 534 features from 8 males and 10 Caucasian females. Each feature is represented by an open
circle, and the differentially expressed features represented as red points in the graph. The dashed lines represent a FDR threshold of 5%. (B)
Distributions of normalized log2 signal intensities of 4 differentially expressed features in males (M1–M8; blue) and females (F1–F10; red). (C)
Hierarchical clustering of samples (males in blue: M1–M8 and females in red: F1–F10) based on summarized intensity values from the 4 differentially
expressed circulating miRNAs. The log2 intensity values are shown in the bar scale.
doi:10.1371/journal.pone.0020769.g007
Analysis of Circulating miRNA Biomarker Signatures
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20769hsa-miR-1292) to be significantly up regulated in females with a
1.63 to 1.94 fold-change in intensity levels (Fig. S4). This fold
increase has also been independently verified through quantitative
PCR for two representative miRNAs (the high abundant hsa-miR-
1292 and low abundant hsa-miR-1323) (Fig. S5). Interestingly, we
did not detect any significantly down regulated miRNAs in this
dataset. For all differential expression analyses the q-value estimates
were found to be significant (Fig. 7B and Fig. S4) [24]. Expression
map of these 4 miRNAs through unsupervised hierarchical
clustering (Fig. 7C) show a clear separation of the two groups with
the exception of 4 female individuals (F1, F3, F5 and F8) indicating
that the miRNA expression profiles between the two groups were
significantly different. We observe a strong and uniform expression
of all up regulated miRNAs (,log2 intensity of 6) across most
individuals with particularly robust expression observed for hsa-
miR-1292 (,log2 intensity of 7.5) (Fig. 7B and C). Taken together
this data characterizes profiles of differentially regulated circulating
miRNAs and reveals distinct gender specific expression patterns for
subsets of miRNAs in cohorts of normal male and female
individuals.
Discussion
In this study we have systematically evaluated the role of heterogeneous
cellular miRNAs derived from disparate hematopoietic cells as a pre-
analytic variable influencing the isolation and analysis of cell-free circulating
miRNAs. Our results show that different fractionation procedures for
plasma have varying degrees of efficacy in the removal of Red and White
Blood Cells and as a consequence can play a major role in impairing
circulating miRNA signatures. Specifically through differential centrifuga-
tion of whole blood into distinct classes of supernatants and pellet fractions
we show disparate distributions of cellular miRNAs and furthermore
demonstrate that the Cloudy Supernatant derived from the first spin is
enriched in contaminant miRNAs compared to isolates of subsequent spins
(S1 and S2) (Fig. 1). Two lines of evidence support this observation. Firstly,
fractionation of the CS isolate leads to a clear separation of signal intensities
between the CS derived, S1 and P1 sub-fractions (Fig. 2A). We observe a
greater magnitude of signal intensity in the CS and P1 isolates compared to
theS1 class, indicativeof thepresence of higher abundant miRNAs in these
fractions. Given the cellular nature of the derivative P1 isolate, we conclude
that a proportion of high abundant cellular miRNAs persist in the CS
fraction that is sequestered in a pellet only as a consequence of additional
c e n t r i f u g a t i o ns t e p( F i g .2 A ) .S e c o n d l y ,inter-fraction Pearson’s correlations
analysis conclusively establishes a strong correspondence between the
contaminants and the contaminant-rich fractions of CS and P1. This
indicates an enrichment of cellular miRNAs in these classes. In contrast a
relatively weaker correlation is seen for the S1 and the S1 derived, S2 and
P2 fractions, suggesting that the miRNA signature of these fractions are
distinct from the cellular class (Fig. 2C ) .W ea l s oo b s e r v et h at ,t h eP 1a n dP 2
pellet fractions are distinctive, with minimal precipitate observed in the P2
isolate. This indicates that the majority of cellular miRNAs are primarily
segregated in the P1 fraction with inconsequential carryover into the P2
isolate. The residual contaminant species detected in the S1 or S2 fraction is
therefore likely to be representative of cellular miRNAs that are present
either due to active release from cells of hematopoietic lineage or are
derived from haemolyis of cells during the isolation process.
Since we observe a high degree of similarity between the S1 and
S2 isolates (Fig. 2C), we chose to focus on the S1 fraction and
assess the advantages of using this fraction over the Cloudy
Supernatant class. We wished to evaluate that the process of
removal of contaminating miRNAs from the CS fraction did not
lead to the loss of abundance or integrity of the circulating species.
We examined the inter-fraction correlations of detected miRNA
intensities stratified into different intensity bins and observe a
strong correlation between the CS and S1 fraction indicating
preservation of circulating species (Fig. 3). We also observe no
significant difference in intensity distributions between stratified
miRNA classes between the CS and S1 fractions supporting the
homogeneity of expression of common representative miRNAs
between these classes (Fig. 4A). The slightly lower intensities in the
S1 fraction are likely due to loss of RNA due to additional
extraction steps. Additionally our analyses also distinguish a clear
reduction in expression of contaminant miRNA signatures in the
S1 fraction compared to the Cloudy Supernatant class (Fig. 4B).
This result conclusively demonstrates that the process of sub-
fractionation enhances the specificity of circulating markers by
removal of cellular miRNA species. Since both the structural and
functional integrity of miRNA populations can be influenced by
procedural effects, we hypothesize that one of the characteristics of
specific circulating miRNA markers should be defined by the
stability of expression across multiple biological samples. In order
to measure reproducibility of expression we examined intensity –
stratified bins of miRNAs in the CS, and S1 fractions across
multiple replicates through Spearman’s Rank Correlation Anal-
ysis. Additionally distribution of CV estimates between the two
fractions across the profiled miRNA dynamic range was also
measured. From both these analyses, we observe (a) statistically
significant increase in expression level correlations across different
miRNA strata in the S1 compared to the CS fraction, indicating
an improved measurement of secretory miRNA population
especially those of higher intensities in the S1 supernatant
(Fig. 5A and B) and (b) a reduction in CV estimates for the S1
fraction compared to the CS isolate demonstrating that the
variability in quantitation of circulating species is reduced as a
result of sub-fractionation of CS into S1. Taken together both
these results strongly affirm the consistency in miRNA signatures
in the S1 supernatant fraction.
It is known that the signatures of plasma/serum miRNAs can
reflect correlations to physiological or disease conditions [10]. To
date 13 types of cancer have been investigated in which
expression profiling of circulating miRNAs have revealed both
diagnostic and prognostic utility for this class of biomarkers [11].
Since gene expression as a quantitative phenotype is known to
vary within a population, in order to obtain miRNA signatures
related to disease classification, it is important to evaluate the
range of inter-individual variability across demographic popula-
tions. To our knowledge no studies have directly explored this
variation in the context of calibrating for cellular miRNA signals.
We sought to assess this variability by mapping the circulating
miRNA expression profiles from the S1 fraction in healthy
population of Caucasian male and female individuals both
through Coefficient of Variation (CV) Analysis and Standard
Deviation (SD) estimates (data not shown) (Fig. 6). Stratification
of miRNAs based on detection in circulation (S) and/or
contaminant (L) classes reveal an approximate loss of 66% of
all detected miRNAs (93 out of 140 miRNAs that are lost
between the +S/+L and the +S/2L classes) through the removal
of cellular miRNA derived signatures. The proportion of this
reduction is comparable to similar extensive overlaps seen
between miRNA profiles derived from plasma micro vesicles
and peripheral blood mononuclear cells [25]. A direct compar-
ison of the 20 most common circulating miRNAs from healthy
individuals over 5 different datasets (reviewed in [12]) reveal, that
in agreement to our study at least 75% (15/20) of the reported
circulating miRNA species can be mapped to our cellular
miRNA signatures (Table S4). Markers that are common to both
the cellular and circulating categories (+S/+L) display a
significantly higher variability in both intensity and variance
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circulation (+S/2L) (Fig. 6A and B). This analysis clearly
indicates that a considerable proportion of cellular miRNAs
persevere in clarified plasma preparation and moreover exhibit
significant variability in expression across different individuals in
a population. Cumulatively this could be reflective of either
varying levels of hematopoietic cell lysis or differences in the
proportion of RNA actively released into circulation from
hematopoietic cells. Calibration of circulating miRNA signals
for specificity though subtraction of these features allows for an
improved estimate of intrinsic variability within individuals.
Additionally, examination of the relationship of 47 miRNAs
(Fig. 6) in the circulatory class to published lists of circulating
miRNAs [26] reveal overlaps between the datasets indicating
detectibility of subsets of these biomarkers across different
experimental platforms (Table S3). Through literature query
and search of two functional databases (miRNAorg:http://www.
microrna.org and miRNAMap: http://mirnamap.mbc.nctu.edu.
tw/) [27] we can find additional correspondence to tissue derived
expression specificity for a subclass of these RNAs [21,22].
Specifically we can map hsa-miR-122, hsa-miR-495, hsa-miR-
34b, hsa-miR-198, hsa-miR -202, hsa-miR-510 and hsa-miR-658
to expression derived from diverse tissues of origin (Table S3),
supporting the hypothesis that non-hematopoietically derived
miRNAs can enter and persist in circulation. The preservation of
these species in a cell-free environment is intriguing. Emerging
evidence point towards sequestration of secretory miRNAs in
sub-cellular particles such as exosomes [19] and microvesicles
[25]. This association provides a model where packaging of
miRNAs allow both for survival in a catalytic extracellular
environment and in addition provide a route for trafficking of
these species through circulation [19] to satisfy a range of
regulatory requirements. Given that the fractionation protocol
utilized in this study preserves the integrity of these sub-cellular
particles in the S1 fraction, it is interesting to speculate on the
involvement of these particles in the potential localization of the
circulatory miRNAs identified in this study.
Gender specific differences are known to play a role not only in
the type and susceptibility of diseases but also affect the response to
therapeutic treatments [28]. In order to assess if the expression of
circulating miRNAs demonstrated any gender specificity we
sought to explore miRNAs signatures in random cohorts of
normal male and female individuals. Through Significance
Analysis of Microarrays (SAM) we distinguished 4 circulating
miRNAs that are differentially expressed in a gender specific
manner. We find all of these miRNAs to be significantly up
regulated by 63–95% in females and detect no miRNAs which
display a reduction in expression (Fig. 7B and C and Fig. S4). We
can verify the fold differences for a subset of these candidates
through qPCR analyses (Fig. S5) and additionally find correlation
of expression of one out of these four miRNAs to sex-specific
tissue. Specifically we show that the strong female specific
expresser: hsa-miR-940 to be detected in the cervix [29] (Fig.
S4). In addition through a search of the Genes-to-Systems Breast
Cancer Database (http://www.itb.cnr.it/breastcancer/) we find
evidence of interaction of all the 4 miRNAs with gene targets such
as E2F1, E2F3, DAPK1 and others implicated to be altered in
breast cancer cells (Fig. S4). Taken together these results provide
functional indications for gender and disease associated role of
these miRNAs. Structurally, we find majority of the differentially
expressed circulating miRNA species (75% or 3/4) originate from
unannotated intergenic regions with only hsa-miR-1292 mapping
to the intron of a gene. Although the biological roles of these
specific miRNAs are obscure, these results thus provide clear
evidence for differential expression of circulating miRNAs in a
gender specific manner. Additionally, correlation of expression to
sex-specific tissues for a subset of these transcripts, provide a
compelling rationale for a physiological role of these miRNAs in
delineating biological differences between the genders.
Several studies have explored the utility and analytical procedures
for the study of circulating miRNAs. Although the precise functions
and mechanism of action of these RNAs remain undetermined
[11,14] accumulating evidence in the form of qPCR and sequencing
data [10,30] from a variety of conditions ranging from malignancies
to pregnancy (reviewed in [12] and [17]) has begun to delineate the
diversity of this class of miRNAs as molecular biomarkers correlating
expression with physiological states. To our knowledge our results
address for the first timecomprehensive global signaturesof bona fide
circulating miRNA species in context of cellular miRNA expression
in cohorts of normal individuals. By segregating the specificity of
measured signals into cell-free and cellular miRNAs we demonstrate
the heterogeneity in expression of fluid-derived biomarker signatures.
Additionally, our data provides categories of miRNAs that can help
distinguish circulating miRNAs from cellular counterparts. The
resultant classifications of these biomarkers into cell-associated and
extracellular circulating species in part help mitigate the inherent
ambiguity in the interpretation of these profiles. Taken together these
results provide a comprehensive map of the circulatory miRNA
environment in normal individuals and provide compelling motiva-
tion to explore such landscapes in detail in pathological conditions,
where circulating miRNA signatures may be further confounded
by disease specific over-expression of hematopoietically derived
miRNAs. As formal recommendations for the study of secretory
biomarkers evolve, we anticipate that analysis of circulating miRNAs
in such class-specific manner would advance both the detection and
quantitation strategies utilized for global investigations of miRNA
biomarker study.
Materials and methods
1. Ethics statement
Anonymized human blood samples were purchased from Stanford
Blood Center (http://bloodcenter.stanford.edu/). Written consent
was obtained from all patients prior to obtaining samples. Stanford
Blood Center is a division of the Stanford University School of
Medicine and complies with allethical guidelines of their Institutional
Review Board. At Affymetrix all applicable OSHA guidelines
(http://www.osha.gov/) for working with human blood samples
were strictly adhered to.
2. Fractionation of plasma from whole blood and
isolation of miRNA
Whole Blood (5–10 mL) was collected from healthy male and
female Caucasian donors; age matched within 25 years in Sodium
EDTA tubes (Table S1). The samples were stored on ice and
processed within 4 hours of draw. All centrifugation steps were
performed at 4uC. All samples were initially spun at 1700 g for 10
minutes to separate the plasma from the Buffy Coat and Red
Blood Cells. Leukocytes were separately isolated from whole blood
stabilized with yeast tRNA (Ambion) and fractionated through
Ficoll-Hypaque gradients. The plasma (designated as the Cloudy
Supernatant) was then re-centrifuged at 2000 g for 10 minutes to
obtain the Supernatant 1 (S1) and Pellet 1 (P1) fractions. F or the
fractionation studies the S1 fraction was additionally centrifuged at
12000 g for 10 minutes to generate the Supernatant 2 (S2) and
Pellet 2 (P2) fractions. All the pellet fractions were washed once
with 1xPBS and then reconstituted in 0.5 ml 1xPBS. Similarly the
Red Blood Cell fraction was washed twice with 3 x volumes of
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Trizol-LS reagent (Invitrogen) and 10 ug/mL of Yeast Total
Carrier RNA (Ambion) were added to stabilize the samples.
Samples were isolated through multiple organic extractions using
0.3 volume of chloroform followed by phenol chloroform
extractions. Total RNA including miRNA was purified from the
aqueous phase using 1.25 volume of ethanol and eluted through
the mirVANA columns (Ambion).
3. Labeling and hybridization of plasma samples to the
Affymetrix miRNA Arrays
Total RNA ranging in concentration from 500–1000 ng were
labeled using the Genisphere HSR labeling kit (P/N HSR30FTA)
and hybridized overnight to the Affymetrix Genechip miRNA
array (P/N 901326) (Table S1). The arrays were washed and
stained using standard Affymetrix protocols and scanned using the
Affymetrix GCS 3000 7G Scanner. Feature intensities were
extracted using the miRNA_1-0_2xgain library files.
4. Analysis of RNA integrity
Total RNA (50-100 ng) was analyzed using the Agilent small
RNA kit in the 2100 Bionalyzer using manufacturer’s recommen-
dations. Additionally for the leukocytic and RBC samples ,300–
400 ng of RNA was resolved on a 15% TBE-UREA gel to
demonstratethe integrity oftotalRNA. This is especially relevant for
samples (i.e. Leukocytes and WBC) where visualization of small
RNA bandsischallenging.Due tolimiting material from one sample
derived from the CS fraction (20100915_RD_Fractionation_
A_Plasma_RNA_800ng_B1_T1.cel) a migration analysis was not
possible. To estimate the integrity of this sample, Pearson’s
correlation of the intensity levels of all normalized human miRNAs
for this specific sample versus all other CS samples in this plasma
class was performed. The computed correlation value is 0.93 with an
R square value of 0.86 indicating a high performance of this sample
in relation to the rest (data not shown).
5. Quantitative RT-PCR
Assays to quantify differential expression of gender specific
miRNAs were performed using the ABI 7500 real-time PCR
instrument and miScript quantitative PCR System (Qiagen).
Pooled Male (M1–M8) and Female (F1–F10) samples were used
for reverse transcription. Approximately 4 ng and 10 ng of cDNA
were used to measure hsa-miR-1292 and hsa-miR-1323 levels,
respectively. The normalizer used in this data was U6. Similar
results are obtained when using miRNAs that are not found to be
differentially expressed by SAM analysis as normalizers (data not
shown). Due to greater sensitivity of the qPCR assay the detected
fold change is on an average 1.3 to 2.5 fold higher than the array
data.
6. Datasets
All data described in this manuscript are MIAME compliant and
have been deposited in NCBI’s Gene Expression Omnibus Database
(http://www.ncbi.nlm.nih.gov/geo/). The data series is accessible
through GEO Series accession number GSE27256: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27256.
7. Analysis of the miRNA data
Data Preprocessing. The workflow for data preprocessing
consisted of extraction of intensities for each individual feature followed
by detection calls based on Wilcoxon-Rank Sum test, background
subtraction based on GC content of anti-genomic probes,
transformation of values through addition of a small constant (value
16), quantile normalization and finally median summarization of all
probe sets for each feature. The detection and background adjustment
were done via Affymetrix miRNA QC Tool and the rest of workflow
was performed under R programming environment (www.r-project.
org) [31]. All reported intensity data are log2 transformed. All p-values
are calculated by two-sided Student’s t-test.
Generation of contaminant features list. For determining
the list of miRNAs that were present in the contamination class,
we first determined the number of detected miRNAs in each of the
3 contaminant categories of Red Blood Cells (RBC), White Blood
Cells (WBC) and Leukocytes (L). A 100% detection criterion (i.e.
present in all of the samples in each category) was applied for
selecting individual miRNAs. A union of all the miRNAs present
in these three classes was then taken to obtain 313 miRNAs that
are co-detected in all these 3 contaminant classes (Table S2).
Analysis of Fractionation Data. For comparison of signal
distributions (Fig. 2A) and rank correlations (Fig. 2C, 3, 4 and 5)
between different plasma (CS, S1, S2, P1 and P2) and cellular
categories (L, W and R), non-normalized data from each fraction
was analyzed to preserve the individual distributions. For inter-
and intra-fraction correlation analyses the average intensities for
all the 847 human miRNAs (Fig. 2C) or 534 human miRNAs that
can be counted after removal of contaminant features (Figs. 3, 4
and 5) were first computed across all samples within an individual
fraction under study. The average intensities were then sorted and
miRNAs binned into different intensity strata. Spearman’s rank
correlation coefficients were calculated for a given set of features in
each intensity bin for comparison between or within a particular
set of fractions.
Analysis of variability Data. For exploration of inter-
individual variability in healthy cohorts of 8 males and 10
females, all individual samples were quantile normalized together
and the numbers of detected miRNAs selected based on the
Wilcoxon-Rank Sum test. Features were then filtered for
contaminant miRNAs and counted based on a 50% detection
threshold for the population under study (i.e. present in at least 9
out of the 18 individuals). Subsequently, selected miRNAs were
stratified into 2 classes based on presence (+) or absence (2)o f
detected features in contaminants (derived from WBC, RBC and
Leukocytes and designated as L) or circulation (S). The number of
miRNAs in the two categories selected were: (a) +S/+L: with 140
features and (b) +S/2L: with 47 features. For each of these classes,
intensity and variability was computed including measurements
from all individuals. Variability estimates were done through
either Coefficient of Variation analysis (Fig. 6B) or Standard
Deviation estimates (data not shown).
8. Gender specific differential expression and Hierarchical
clustering of intensity data
For exploration of gender specific differential expression,
normalized summarized intensities from 8 males and 10 females
were analyzed using Significance Analysis of Microarray data
(SAM) [32]. All 534 features were included in this analysis after
removal of contaminant miRNAs and features with significant
differential expression levels (DE) detected at a false discovery rate
(FDR) of 5%. Expected scores were calculated though 1000
permutations in SAM. A total of 5 DE features were determined
which were subsequently filtered for detection calls and miRNAs
not detected in any samples were removed (Fig. 7A). This process
resulted in the elimination of hsa-miR-1181. From this analysis a
total of 4 up-regulated features were distinguished in females
(Fig.7B, C and Fig. S4). Statistical significance of differential
expression was measured by the q-value which is an estimate of
FDR and is usually a number greater than 0. In our dataset due to
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the test statistic of a feature is more extreme than all observed
permutations. This indicates that the estimated FDR, by declaring
this feature as significant, is equivalent to 0. All differentially
expressed features were further selected for clustering to delineate
relationships between the two sexes. The unsupervised Hierarchi-
cal clustering algorithm in the R ‘‘hclust’’ function was used with
Euclidean distance matrix and complete-linkage agglomeration.
The heat map was generated by the R ‘‘gplots’’ package (Fig. 7C).
All gender specific features were mapped to the April 2010
mirBASE release 16 to get chromosomal and genomic locations.
Supporting Information
Figure S1 (A–I). Agilent 2100 Bioanalyzer and PAGE analysis
of RNA integrity for samples used in this study.
(TIF)
Figure S2 Box plot of signal intensity distribution of human
miRNAs (white) and background probes (red) for 8 males and 10
females after background subtraction, quantile normalization and
median summarization.
(TIF)
Figure S3 Box plot of signal intensity distribution of 47 human
miRNAs specific only to circulation (+S/2L) in healthy cohorts of
8 male and 10 female individuals.
(TIF)
Figure S4 Table of statistically significantly differentially ex-
pressed miRNA features in females compared to males based on
SAM analysis. The ‘‘Score’’ represents the modified t-test statistics
calculated by SAM. The ‘‘Fold Change’’ denotes the ratios of the
mean intensity in female samples over male samples. Tissue
specific expression is derived from mirBASE, miRNAorg or
miRNAmap databases.
(TIF)
Figure S5 (A–B). Expression levels of hsa-miR-1292 and hsa-
miR-1323 (n=4, *P values ,0.01) measured by qPCR. The p
values are calculated based on a Student’s t-test of the replicate
2‘(2DCt) values for each miRNA in the control group (males) and
test groups (females).
(TIF)
Table S1 List of experimental datasets.
(XLSX)
Table S2 List of 313 miRNAs in the contamination list. Un-
normalized intensity values and detection calls from each sample
are represented.
(XLSX)
Table S3 List of 140 miRNAs common to both circulation and
in contaminants (+S/+L) or 47 miRNAs specific only to
circulation (+S/2L). Normalized intensity values and detection
calls from each sample are represented.
(XLSX)
Table S4 Overlap of 20 most common circulating miRNAs
from healthy individuals and 140 miRNAs present in the +S/+L
category.
(XLS)
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